Autori: Tan Antoinette R
| Naslov | Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2 (Article) |
| Autori | Goel Shom Tan Antoinette R Rugo Hope S Aftimos Philippe Andric Zoran G Beelen Andrew Paul Zhang Jingshan Yi John S Malik Rajesh K O'Shaughnessy Joyce |
| Info | FUTURE ONCOLOGY, (2022), vol. 18 br. 33, str. 3701-3711 |
| Projekat | G1 Therapeutics; Eli Lilly; Merck; Pfizer; AstraZeneca; Ayala; Boehringer Ingelheim; Daiichi; Gilead; Lilly; Macrogenics; Novartis; OBI; Odonate; Polyphor; Roche; Seattle Genetics; Sermonix |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science |
| Naslov | Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study (Article) |
| Autori | Tan Antoinette R ... Popovic Lazar S ... Milenkovic Dusan M ... (broj koautora 17) |
| Info | CLINICAL CANCER RESEARCH, (2022), vol. 28 br. 4, str. 629-636 |
| Projekat | G1 Therapeutics, Inc. |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science Scopus |
| Naslov | Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial (Article) |
| Autori | Tan Antoinette R ... Popovic Lazar S ... Milenkovic Dusan M ... (broj koautora 17) |
| Info | LANCET ONCOLOGY, (2019), vol. 20 br. 11, str. 1587-1601 |
| Projekat | G1 Therapeutics |
| Ispravka | ISI/Web of Science Članak Elečas Rang časopisa Citati: ISI/Web of Science Scopus |
